Since the US FDA approved immunotherapy in 2015, immuno-oncology has completely changed the treatment of non-small cell lung cancer (NSCLC) and has become a new and effective treatment.However, the overall effectiveness of immunotherapy is only 20% to 30%, only a small number of patients can benefit from it, and it also produces a series of toxic side effects.Studies have shown that tumor-infiltrating lymphocytes (TILs) are associated with a variety of tumor outcomes, especially in lung cancer.Therefore, there is still room to improve outcomes for patients with non-small cell lung cancer.Finding efficient and accurate biomarkers to predict and screen cancer patients with good efficacy for PD-1/PD-L1 inhibitor therapy has become an important clinical research hotspot and urgent need.The purpose of this review is to elucidate the clinical significance of TILs and PD-L1 expression in NSCLC and its correlation with prognosis, and to provide clinical reference for patients receiving immunotherapy.

Xinmei Wang, Zhiqiong Yu, Weihua Hu. Clinical significance and prognostic analysis of TILs and PD-L1 expression in non-small cell lung cancer. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 5: 27-32. https://doi.org/10.25236/IJFM.2024.060505.

[1] S D E ,E D W ,L D A , et al.Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.[J].Journal of the National Comprehensive Cancer Network : JNCCN,2022, 20(5): 497-530.

[2] Suresh K , Naidoo J , Lin C T ,et al.Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer[J].Chest, 154(6)[2023-12-11].DOI:10.1016/j.chest.2018.08.1048.

[3] Genova C , Dellepiane C , Carrega P ,et al.Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade[J].Frontiers in Immunology, 2022, 12.DOI: 10. 3389/ fimmu.2021.799455. 

[4] Moreno V , Salazar R , Gruber S B .The prognostic value of TILs in stage III colon cancer must consider sidedness[J].Annals of oncology : official journal of the European Society for Medical Oncology, 2022, 33(11):1094-1096.DOI:10.1016/j.annonc.2022.09.155.

[5] Giatromanolaki A , Anestopoulos I , Panayiotidis M I ,et al.Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients[J].Anticancer Research, 2021, 41(8):3989-3995.DOI:10.21873/ anticanres. 15196.

[6] Bagaev A, Kotlov N, Nomie K,et al.Conserved pan-cancer microenvironment subtypes predict response to immunotherapy[J].Cancer Cell, 2021.DOI:10.1016/j.ccell.2021.04.014.  

[7] T S P,Annegé V,Marco B D, et al.Tumor-infiltrating lymphocytes in the immunotherapy era.[J].Cellular molecular immunology,2020,18(4):842-859.

[8] Zhang L , Chen Y , Wang H ,et al.Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer[J].Journal for immunotherapy of cancer, 9(6):e002356[2024-04-12].DOI:10.1136/jitc-2021-002356.

[9] Creelan B , Wang C , Teer J ,et al.Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial[J].Nature Medicine, 2021, 27:1410 - 1418.DOI:10.1038/s41591-021-01462-y.

[10] Alexander M ,Kilian W ,Jianda Y , et al.Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.[J].Clinical cancer research : an official journal of the American Association for Cancer Research,2016,22(19):4848-4858.

[11] Amélie Cachot, Bilous M , Liu Y C ,et al.Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer[J].Science Advances, 2021, 7(9):eabe3348.DOI:10.1126/sciadv.abe3348.

[12] Oliveira G , Stromhaug K , Cieri N ,et al.Landscape of helper and regulatory antitumour CD4~+ T cells in melanoma[J].Nature, 2022(May 19 TN.7910):605.

[13] Chen B , Li H , Liu C ,et al.Prognostic value of the common tumour-infiltrating lymphocyte subtypes for patients with non-small cell lung cancer: A meta-analysis[J].PLoS ONE, 2020, 15(11):e0242173. DOI: 10.1371/journal.pone.0242173.

[14] Giatromanolaki A , Anestopoulos I , Panayiotidis M I ,et al.Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients[J].Anticancer Research, 2021, 41(8):3989-3995.DOI:10.21873/ anticanres. 15196.

[15] Teng F , Meng X , Wang X ,et al.Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions[J].Oncotarget, 2016, 7(39):64318-64329.DOI:10. 18632/ oncotarget.11793.

[16] William,Sterlacci,Michael,et al.Expression of PD-L1 Identifies a Subgroup of More Aggressive Non-Small Cell Carcinomas of the Lung.[J].Pathobiology : journal of immunopathology, molecular and cellular biology, 2016.DOI:10.1159/000444804.

[17] Jamiyan T , Kuroda H , Yamaguchi R ,et al.CD68- and CD163-positive tumor-associated macrophages in triple negative cancer of the breast[J].Virchows Archiv, 2020, 477(6).DOI:10. 1007/s00428-020-02855-z.

[18] Yoneda K , Kuwata T , Kanayama M ,et al.Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer[J].British Journal of Cancer, 2019, 121(6).DOI:10.1038/s41416-019-0541-3.

[19] Zens P , Bello C , Scherz A ,et al.The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer[J].Modern Pathology[2024-04-12].DOI: 10. 1038/ s41379-022-01139-y.

[20] A S H , A M F F , A A N ,et al.Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study - ScienceDirect[J].Lung Cancer, 2021.DOI:10.1016/j. lungcan. 2021. 01.013.